The medication is commonly used to address conditions characterized by excessive or prolonged blood loss, and is applied across domains where additional symptomatic support is needed. It is relevant in clinical settings involving heavy menstrual bleeding (menorrhagia) or unexpected bleeding between cycles (metrorrhagia), as well as persistent capillary oozing after surgical procedures (e.g., dental or ENT), and conditions leading to recurrent nosebleeds (epistaxis). In specialized settings, it is applied in high-risk populations, such as premature infants, to help manage the risk of internal hemorrhage. This supportive approach contributes to easing the overall symptom load and may help maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Capillary Bleeding The medication is applied in conditions where symptoms are related to localized vascular strain.

“This therapeutic support is relevant for easing symptoms related to heightened physiological activity, helping patients cope more steadily with symptom fluctuations.”

The official eligibility profile for Дицинон (Etamsylate) is defined by a set of strict contraindications and conditional limitations established in regulatory labeling.

Absolute Contraindications	Conditional/Restricted Use
Acute Porphyria	Pregnancy: Caution is required due to the absence of human clinical data.
Hypersensitivity to etamsylate or excipients	Lactation/Breastfeeding: Inadvisable; treatment must be stopped if breastfeeding continues.
Bronchial Asthma or confirmed sulphite allergy	Hepatic/Renal Impairment: Caution is required because dedicated clinical studies have not been performed in these populations.

The medicine is strictly prohibited for use in patients with these absolute contraindications. Regarding age-related use, the drug is explicitly indicated for use in low birth weight infants (under 1.5 kg) for specific conditions; however, treatment must be discontinued immediately if the infant develops a fever. Use in adults is generally allowed, but caution is required during injection for patients with unstable pressure or hypotension due to the risk of a blood pressure fall. Eligibility is always determined by the absence of documented prohibitions and adherence to these conditional use restrictions.

Interactions with other medicines and products

The official regulatory profile for Etamsylate (Дицинон) is primarily defined by Administration Incompatibility Restrictions for its parenteral (injectable) form. Documented interaction information focuses on mandatory constraints and prohibitions related to the chemical properties of the Etamsylate solution and its mixing with specific intravenous products.

---

Administration-Related Constraints

The following substances and solutions are subject to strict regulatory constraints regarding co-administration or mixing with Etamsylate solution, reflecting documented incompatibilities or pharmacodynamic inactivation risks:

Interacting Substance	Official Interaction Pattern	Context
Solutions of Sodium Bicarbonate	Chemically incompatible; mixing is prohibited.	Intravenous solutions
Compound Sodium Lactate solutions	Chemically incompatible; mixing is prohibited.	Intravenous solutions
Thiamine (Vitamin B1)	Inactivated by the sulphite contained in the Etamsylate solution.	Co-administration may lead to inactivation of Thiamine.
Dextran Infusion	Mandatory administration sequence: Etamsylate must be injected first.	Administration timing rule

---

The regulatory profile does not contain explicit documentation detailing systemic drug-drug interactions involving common metabolic enzymes or transporters. The documented constraints serve to maintain the chemical stability and activity of the medication and prevent the inactivation of certain co-administered medicinal products, defining the specific scope of this drug's official interaction profile.

Capillary Wall Stabilization (Angioprotection)

The primary mechanism involves increasing the mechanical resistance of the capillary endothelial cells by promoting the local synthesis of structural molecules, such as Hyaluronic Acid. This reinforcement results in decreased permeability of the vessel walls and restricts the passive movement of blood elements across the vessel wall barrier.

---

Enhancement of Primary Hemostasis

Etamsylate modulates the initial, physical phase of blood clotting. It enhances platelet adhesion and subsequent aggregation by influencing local mediators and increasing the expression of surface adhesion molecules like P-selectin. Concurrently, the drug selectively inhibits the synthesis of the anti-aggregatory mediator Prostacyclin (PGI2), locally shifting the eicosanoid balance to favor the development of the hemostatic plug.

---

Mechanistic Scope

This dual action modulates processes within the microcirculation and is focused exclusively on the primary hemostasis cascade. The mechanism does not engage or affect the secondary hemostasis (plasma coagulation factor cascade) and has no influence on the overall number of circulating platelets.

Official Administration Instructions for Etamsylate (Дицинон)

The administration of Etamsylate follows distinct protocols for acute versus sustained usage, based on its available forms: the 500 mg oral tablet/capsule and the 250 mg/2 ml solution for injection. The routes include Oral, Intravenous (i.v.), Intramuscular (i.m.), and localized Topical application of the injection solution.

Dosing and Frequency Patterns

The dose and frequency are structured according to the clinical context.

Context	Dose and Route	Frequency and Timing
Surgical (Parenteral)	250 mg to 500 mg i.v. or i.m.	Administered one hour before the procedure; repeated every 4 to 6 hours post-operatively.
Cyclic (Oral)	500 mg per dose.	Taken 3 times per day for a 10-day course, starting 5 days prior to the expected onset of menstruation.

Specific Administration Conditions

Oral administration is generally advised to be taken with meals along with water. For the parenteral solution, it must not be mixed with specific incompatible solutions, such as sodium bicarbonate, and must be administered immediately if diluted with saline. Blood samples for laboratory testing should be collected prior to the first daily dose.

Population Rules

A specific regimen is specified for low birth weight neonates (less than 1.5 kg), requiring a dose of 12.5 mg/kg i.v. or i.m. within the first hour of life, repeated every six hours for the subsequent four days. Caution is noted for use in patients with renal or hepatic impairment, though a universal dose adjustment is not mandated in the standard labeling.

Research Evidence: Overview of Studies for Etamsylate

This section provides a factual summary of the clinical studies and official research base for Etamsylate (Дицинон), focusing on the types of evidence, the populations studied, and the research gaps acknowledged by regulators and scientific literature. The information presented here summarizes research patterns and does not offer clinical advice or individual guidance.

---

Evidence for Use in Heavy Menstrual Bleeding (Menorrhagia)

Research for heavy menstrual bleeding (menorrhagia) was conducted using Randomized Controlled Trials (RCTs) and systematic reviews. Studies were applied in research contexts involving fluctuating or episodic manifestations of heavy bleeding in women of reproductive age. Studies monitored patient-reported outcomes describing perceived discomfort and measures of systemic symptoms over a defined time interval, typically covering three or four consecutive cycles. Research highlights changes measured during the study period, with findings often described patterns related to changes in the total estimated volume of menstrual blood loss. However, evidence quality varies across studies, with some older trials having modest sample sizes or limitations in their design, and findings were mixed across different studies.

Research Focused on Hemorrhage in Premature Infants

Etamsylate was studied in research exploring bleeding patterns in highly specialized populations, particularly very low birth weight or premature infants. These studies were conducted during periods of increased physiological stress in a neonatal intensive care setting and are often linked to regulatory documentation for Orphan Drug status. Research examined critical outcomes by monitoring the incidence and severity of cerebral hemorrhage (Periventricular Hemorrhage, or PVH) and assessing patterns related to mortality. Data show patterns related to these critical measures in the neonatal population; however, results apply only to the populations studied, and the variability of findings may be observed due to differences in intensive care practices across different clinical centers.

What Remains Uncertain: Research Gaps and Limitations

For most studied conditions, long-term effects or the maintenance of observed patterns after treatment is stopped are an area where evidence remains limited. Comparative evidence is lacking in some areas, particularly large-scale studies against newer alternative treatments. Key limitations include small sample sizes in some of the older trials and the fact that findings were mixed across different studies and populations. For rare conditions like Hereditary Haemorrhagic Telangiectasia, research is ongoing, meaning definitive clinical data are still emerging, and a comprehensive understanding is not yet available.

Key Studies & References

1. WHO ATC/DDD Index: Etamsylate (B02BX01) Classification
2. Randomized Controlled Trial of Etamsylate in Surgical Bleeding (Hypothetical Placeholder)

Common questions about Дицинон (FAQ)

Q: Is Дицинон appropriate for bleeding related to dental procedures?

Official product information describes the drug's general purpose as controlling or limiting bleeding, particularly in postsurgical scenarios involving small blood vessels. The drug’s mechanism and general purpose are related to managing capillary bleeding, which is a type of bleeding that can occur in postsurgical settings.

Q: Can children use Дицинон?

Regulatory documents include a specific regimen for use in low birth weight neonates for certain conditions. Use in children outside of this defined group is an individualized medical decision.

Q: Does Дицинон interact with common pain relievers like ibuprofen?

Official regulatory documents generally lack explicit information on systemic interactions with common pain relievers like ibuprofen. However, a warning for caution exists when the drug is used alongside other medicines that affect platelet function (the initial phase of clotting).

Q: Are there known interactions between Дицинон and blood pressure medications?

Systemic drug-drug interactions with blood pressure medications are not explicitly documented in official sources. A safety note is included for the injectable form, which warns that administering it too quickly may cause a transient drop in blood pressure (hypotension).

Q: Is it normal to feel dizzy after using Дицинон?

Official reporting on possible side effects has noted occurrences of dizziness. Official warnings state that if side effects such as dizziness occur, activities like driving or operating machinery should be avoided.

Q: Is there a maximum time frame for using Дицинон, as described in official guides?

The defined official regimens for the drug are typically for short-term use to manage specific bleeding events. For example, its regimen for heavy menstrual bleeding specifies a 10-day course. Long-term continuous use is not generally recommended in regulatory documents.

Q: Can Дицинон be used to stop minor nosebleeds?

The general purpose of this medicine, as described in regulatory sources, is to limit and control capillary bleeding (bleeding from small blood vessels). The drug’s function is to limit and control capillary bleeding, which is a type of bleeding that can occur in conditions like nosebleeds (epistaxis).

Q: What does the term 'antihemorrhagic' mean in simple terms?

The drug is officially classified as a Systemic Haemostatic Agent, which means it works throughout the body to assist the natural processes that stop or control bleeding. The term antihemorrhagic is essentially a synonym for this pharmacological class.

Q: Does Дицинон interact with anticoagulants like Warfarin?

Official documents advise caution when this medicine is used at the same time as anticoagulant medications (or blood thinners) like Warfarin.

Q: Why do people sometimes confuse Дицинон with a clotting factor medication?

The confusion may stem from its classification as a haemostatic agent (a medicine that helps stop bleeding). Official sources clarify that it specifically reinforces primary hemostasis (capillary walls and platelets) but does not affect the secondary coagulation factor cascade, which is how clotting factor medications work.

Q: How quickly does Дицинон start to work?

Pharmacokinetic studies provide information on how the body handles the medicine. Data for the oral form indicates the drug reaches its maximum concentration in the blood approximately 5 hours after administration.

Q: What is the typical duration of Дицинон's effect?

The elimination half-life (T1/2) of the oral form is about 9.4 hours, according to pharmacokinetic studies. This is the time required for the amount of drug in the body to be reduced by half.

Q: What does the research say about Дицинон's use in postpartum hemorrhage?

Official research overviews state that studies have been conducted to examine the drug’s potential role in managing bleeding associated with various clinical contexts, which includes postpartum hemorrhage. Findings from these research areas contribute to the overall understanding of the drug's application.

Q: Are there any warnings about driving or operating machinery while on Дицинон?

Official documents include a warning that if side effects such as dizziness or headache occur, the ability to drive or operate machinery may be affected.

Q: Is Дицинон used in veterinary medicine, according to official reports?

Yes, the regulatory framework includes the use of Etamsylate in veterinary medicinal products. For example, the European Medicines Agency (EMA) has adopted official documentation related to its use in animals.

Q: Can I use alcohol while taking Дицинон?

Due to a lack of dedicated studies examining the specific interaction, official product information may advise caution regarding alcohol consumption while using this medicine.

Q: Are there any warnings for elderly patients using Дицинон?

Official documents often note that specific clinical information on the use of the drug in patients older than 65 years of age is often limited. This indicates that use in this population requires an individualized medical assessment.

Q: How long after stopping Дицинон is it fully cleared from the body?

The rate at which the body clears a drug is linked to its elimination half-life (T1/2). Since the T1/2 of the oral form is about 9.4 hours, it typically takes several half-lives for the drug to be considered fully eliminated from the system.

How to Store and Dispose of Dicynone (Etamsylate)

The storage and disposal of Dicynone must strictly follow the requirements defined in the official regulatory product labeling.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 30^circC (for injection solution).
Protection	Must be protected from light and heat.
Packaging	Keep the medicine in the original package.

Stability and Safety

To ensure product stability, the injection solution must be discarded if it has become coloured. The medicine must be kept out of the sight and reach of children to prevent accidental ingestion or misuse. Additionally, Dicynone must not be used after the expiration date (EXP) printed on the packaging.

Disposal Instructions

All unused or expired Dicynone must be disposed of according to local regulations for pharmaceutical waste, following the instructions of a healthcare professional or local authorities.